Tivic Health Systems (NASDAQ:TIVC) Issues Earnings Results

Posted by Teresa Graham on Nov 16th, 2025

Tivic Health Systems (NASDAQ:TIVC – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($2.00) EPS for the quarter, FiscalAI reports. Tivic Health Systems had a negative net margin of 148.49% and a negative return on equity of 22.69%. The company had revenue of $0.15 million during the quarter.

Tivic Health Systems Stock Performance

Tivic Health Systems stock traded down $0.17 during midday trading on Friday, hitting $1.91. 385,091 shares of the company’s stock were exchanged, compared to its average volume of 40,987. The stock has a market cap of $2.06 million, a price-to-earnings ratio of -0.22 and a beta of 1.96. Tivic Health Systems has a 12-month low of $1.74 and a 12-month high of $15.64. The firm’s 50 day simple moving average is $2.80 and its 200 day simple moving average is $3.47.

Institutional Investors Weigh In On Tivic Health Systems

A hedge fund recently bought a new stake in Tivic Health Systems stock. Marex Group plc purchased a new stake in Tivic Health Systems, Inc. (NASDAQ:TIVC – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 39,283 shares of the company’s stock, valued at approximately $163,000. Marex Group plc owned 3.64% of Tivic Health Systems as of its most recent SEC filing. Institutional investors own 4.25% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tivic Health Systems in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Read Our Latest Analysis on Tivic Health Systems

Tivic Health Systems Company Profile

(Get Free Report)

Tivic Health Systems Inc operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S.